Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg

Executive Summary

Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg

You may also be interested in...



Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed

The restructured Pfizer/Pharmacia sales force will begin operations in June

Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed

The restructured Pfizer/Pharmacia sales force will begin operations in June

Ortho-McNeil Adds Axert To Pain Portfolio; Pfizer Left With One Triptan

Ortho-McNeil will enter the triptan migraine class by taking over Pharmacia's marketing rights to Axert

Related Content

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel